"patients with lung cancer" trang 7 - tải miễn phí từ tailieuXANH
Risk factors of metachronous brain metastasis in patients with EGFR-mutated advanced non-small cell lung cancer

Risk factors of metachronous brain metastasis in patients with EGFR-mutated advanced non-small cell lung cancer
11    136    0
A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506)

A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506)
7    103    0
Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification

Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification
10    132    0
Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease smallcell lung cancer (LD-SCLC): TORG 0604

Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease smallcell lung cancer (LD-SCLC): TORG 0604
9    94    0
Frequency of the acquired resistant mutation T790 M in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R: A systematic review and meta-analysis

Frequency of the acquired resistant mutation T790 M in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R: A systematic review and meta-analysis
7    73    0
Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016

Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016
8    80    0
Underutilization and disparities in access to EGFR testing among Medicare patients with lung cancer from 2010 – 2013

Underutilization and disparities in access to EGFR testing among Medicare patients with lung cancer from 2010 – 2013
13    47    0
Comparing biological information contained in mRNA and non-coding RNAs for classification of lung cancer patients

Comparing biological information contained in mRNA and non-coding RNAs for classification of lung cancer patients
15    77    0
Application of Ventana immunocytochemical analysis on ThinPrep cytology slides for detection of ALK rearrangement in patients with advanced non–small-cell lung cancer

Application of Ventana immunocytochemical analysis on ThinPrep cytology slides for detection of ALK rearrangement in patients with advanced non–small-cell lung cancer
8    53    0
The prognostic impact of decreased pretreatment haemoglobin level on the survival of patients with lung cancer: A systematic review and meta-analysis

The prognostic impact of decreased pretreatment haemoglobin level on the survival of patients with lung cancer: A systematic review and meta-analysis
15    49    0
Satisfactory results of a psychometric analysis and calculation of minimal clinically important differences of the World Health Organization quality of lifeBREF questionnaire in an observational cohort study with lung cancer and mesothelioma patients

Satisfactory results of a psychometric analysis and calculation of minimal clinically important differences of the World Health Organization quality of lifeBREF questionnaire in an observational cohort study with lung cancer and mesothelioma patients
12    57    0
Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study

Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study
7    55    0
Impact on prognosis of rebiopsy in advanced non-small cell lung cancer patients after epidermal growth factor receptor-tyrosine kinase inhibitor treatment: A systematic review

Impact on prognosis of rebiopsy in advanced non-small cell lung cancer patients after epidermal growth factor receptor-tyrosine kinase inhibitor treatment: A systematic review
5    62    0
Different next-generation sequencing pipelines based detection of tumor DNA in cerebrospinal fluid of lung adenocarcinoma cancer patients with leptomeningeal metastases

Different next-generation sequencing pipelines based detection of tumor DNA in cerebrospinal fluid of lung adenocarcinoma cancer patients with leptomeningeal metastases
8    69    0
The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: A combined analysis of 388 patients with 500 metastases

The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: A combined analysis of 388 patients with 500 metastases
12    57    0
Efficacy and risk of cytotoxic chemotherapy in extensive disease-small cell lung cancer patients with interstitial pneumonia

Efficacy and risk of cytotoxic chemotherapy in extensive disease-small cell lung cancer patients with interstitial pneumonia
7    50    0
Nomogram based on homogeneous and heterogeneous associated factors for predicting bone metastases in patients with different histological types of lung cancer

Nomogram based on homogeneous and heterogeneous associated factors for predicting bone metastases in patients with different histological types of lung cancer
12    85    0
EGFR mutation frequency in Middle East and African non-small cell lung cancer patients: A systematic review and metaanalysis

EGFR mutation frequency in Middle East and African non-small cell lung cancer patients: A systematic review and metaanalysis
6    246    0
Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316)

Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316)
6    65    0
A molecular and staging model predicts survival in patients with resected non-small cell lung cancer

A molecular and staging model predicts survival in patients with resected non-small cell lung cancer
8    52    0
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.